期刊
CELL
卷 147, 期 5, 页码 1011-1023出版社
CELL PRESS
DOI: 10.1016/j.cell.2011.09.055
关键词
-
资金
- NIH [HL59949, 5R01MH084894, MH084894, MH091360, DA026434, F30HL097582, SRC1DA02811202, 1R01DA02694702]
- NARSAD
- Dainippon Sumitomo Pharma
- Maltz Family Foundation
- National Science Foundation [TG-MCB080109N]
- Ministerio de Ciencia e Innovacion, Spain
Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT2A G protein-coupled receptor (GPCR), the 2AR, which signals via a G(q) heterotrimeric G protein. The closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 2AR function, but they lack comparable neuropsychological effects. Why some but not all 2AR inhibitors exhibit antipsychotic properties remains unresolved. We now show that a heteromeric complex between the 2AR and the Gi-linked GPCR, metabotropic glutamate 2 receptor (mGluR2), integrates ligand input, modulating signaling output and behavioral changes. Serotonergic and glutamatergic drugs bind the mGluR2/2AR heterocomplex, which then balances Gi- and Gq-dependent signaling. We find that the mGluR2/2AR-mediated changes in Gi and Gq activity predict the psychoactive behavioral effects of a variety of pharmocological compounds. These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据